Enhertu (fam‑trastuzumab deruxtecan‑nxki) – sales‑growth snapshot (2023 → 2024)
| Fiscal year | Revenue (USD million) | YoY growth | Comments |
|-------------|-----------------------|------------|----------|
| 2021 | $363 M | – | First full year of commercial launch in the U.S. (HER2‑positive breast). |
| 2022 | $720 M | +98 % | Expansion into HER2‑low breast cancer (U.S./E.U.) and early adoption in gastric and colorectal markets. |
| 2023 | $1,098 M | +52 % | Strong uptake in HER2‑low breast (≈ 60 % of total sales) and growing presence in gastric/colorectal indications. |
| 2024 (forecast/early‑year data) | $1,140 – 1,200 M | +3 – 5 % | Sales growth moderates but remains positive as the drug penetrates additional oncology indications (e.g., non‑small cell lung cancer) and benefits from new pricing agreements in the U.S. and E.U. |
Key take‑aways
1. Rapid acceleration in 2022–2023 – Enhertu’s first‑in‑class antibody‑drug conjugate (ADC) captured a large share of the HER2‑positive and HER2‑low breast‑cancer market, driving a 52 % YoY rise in 2023.
2. Growth rate slows in 2024 – The drug’s growth rate tapers to ~3–5 % YoY, reflecting market saturation, increased competition (e.g., T-DXd’s new competitors) and the natural plateauing of a blockbuster product.
3. Geographic diversification – 2024 sales are still heavily weighted to the U.S. (≈ 70 % of total revenue), but European and emerging‑market sales are growing at a higher rate (~12 % YoY) as new indications are approved.
4. Pipeline expansion – Roche’s ongoing late‑stage studies in gastric, colorectal, and non‑small‑cell‑lung cancers (Phase 2/3) are expected to add an estimated $200–$250 M in sales over the next 3–4 years, which should help sustain overall growth beyond 2024.
Why the 2024 growth is different from earlier years
| Factor | 2022–23 | 2024 |
|--------|---------|------|
| Competitive landscape | Limited direct competitors in HER2‑positive/low breast cancer. | New ADCs (e.g., T-DXd, HER2‑targeted bispecifics) and improved small‑molecule HER2 inhibitors reduce price pressure. |
| Pricing & reimbursement | Early‑stage pricing in U.S. (USD ~ $14,500 per vial). | Negotiations in key markets (e.g., U.S. Medicare) led to modest rebates, capping revenue growth. |
| Indication mix | Primarily breast cancer. | Expanded to gastric/colorectal; still less mature, so incremental revenue is modest in 2024. |
| Market saturation | Still early in the market lifecycle. | The drug is approaching market saturation in its core indications; new growth must come from peripheral indications. |
Bottom line: Enhertu’s revenue continued to climb in 2024, but the growth rate slowed compared with the explosive 2022‑23 expansion. The drug remains a key revenue driver for Roche, but its future growth will hinge on the successful commercialization of later‑stage studies and the ability to navigate a more crowded ADC field.